Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (32611)	8/22/2000 11:07:19 AM
From: KM	Read Replies (1) \| Respond to of 57584

Rande: Add HAXS to the small internets. It trades nearly indentically with HLTH. Severely beaten down . . . nearly everyone is out - should not be much tax selling - and nowhere to go but up. Former CEO of Aetna joined them today. Huge huge short position and very thin. Can move quickly.

To: Rande Is who wrote (32611)	8/22/2000 12:11:09 PM
From: Mark Konrad	Read Replies (1) \| Respond to of 57584

Cults, Caps, Craps! Great post but I don't know if ALL buying is totally short-related. As you suggest, sometimes it doesn't matter if the trade is based purely on oversold conditions or momentum. The "cult" moniker is perhaps too negative in its connotation for issues with increasing profits and increasing revenues in growing sectors: WFII, NTRO, JNIC, and FNSR to name a few. If shorts and cash-strapped longs have indiscriminately sold the wheat with the chaff, we just have to look more carefully for the wheat (or really, really cheap chaff!). Buying something, anything, just because it's cheap is a lousy way to invest and only sometimes a successful way to trade. Charts and balance sheets are two of the three pillars of sound investing and trading. The third is money management. This has been, and will continue to be, a "picker's" market, imo. Technical Analysis helps optimize entry and exit points while money management techniques keep us from becoming wards of the State and eating government cheese! Thanks for the dose of "rational" exuberance!--Mark--

To: Rande Is who wrote (32611)	8/22/2000 1:34:43 PM
From: American Spirit	Read Replies (2) \| Respond to of 57584

ESHR and ELNK the best beaten down internet type stocks I know. ESHR selling for less than one year's revenues and may break a profit next quarter. Special buy alert now at 3 1/2 which should be the absolute bottom. ELNK up since I called it but still dirt cheap selling for 30% more than the cash it has in the bank. ESHR has had terrible low volume for awhile now but boy if it ever catches the spotlight again. And why not? A hot smaller B2B company with terrific prospects going forward. NOVL's new e-commerce solutions announcement sounds hot. Expect a spin-off from them soon if not a takeover. VZ hasn't popped since the strike ended? Doesn't make sense. A PE of 10 for America's #1 wireless and DSL company.

To: Rande Is who wrote (32611)	8/28/2000 10:01:19 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 57584

CNQR has a cult following? Heh, you wouldn't know it by the thread here on SI, maybe I'll have to lurk on the Yahoo thread. Anyway, I should think down here around 3 5/8 (or should I say .625? ) is a good place to buy a first third, maybe a second third in October with one more lousy earnings, and the final batch on the trend back up someday. Seems like if you matched up Concur with something like a Datachannel (another local one to me) you might have a pretty interesting company. Also in for first thirds of Novel and Informix, just edging out of some of my biotechs into a little software. Also half cash. Also, I wanted to say something about this... Rande wrote The usual names apply. . . CRA, PDLI, HGSI, MLNM, MYGN, INCY, GENE, GNSL, GLGC, etc., etc., etc. [this group will soon have more names than the Dot Coms.] The recent flood of biotech IPOs is part of the reason I've moved out of the sector to some degree--too much damn product (but also to lock in some gains, something I failed to do back in March) But really, isn't every sector drowning in too many names? Maybe what is going to happen is all this new money in biotech will help to gobble up the forgotton names out there--there are a number of biotechs that did not participate in the big biotech funding grab this year--some are some good companies with piles of patents etc. I hope we see buyouts in biotechland, and that is where I still have some money--the orphans and widows.